These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36103178)

  • 1. Estimated Cost of Developing a Therapeutic Complex Medical Device in the US.
    Sertkaya A; DeVries R; Jessup A; Beleche T
    JAMA Netw Open; 2022 Sep; 5(9):e2231609. PubMed ID: 36103178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.
    Wouters OJ; McKee M; Luyten J
    JAMA; 2020 Mar; 323(9):844-853. PubMed ID: 32125404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of Drug Development and Research and Development Intensity in the US, 2000-2018.
    Sertkaya A; Beleche T; Jessup A; Sommers BD
    JAMA Netw Open; 2024 Jun; 7(6):e2415445. PubMed ID: 38941099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
    Rathi VK; Krumholz HM; Masoudi FA; Ross JS
    JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Regulation and Approval of Medical Devices: 1976-2020.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2021 Aug; 326(5):420-432. PubMed ID: 34342614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Recall Among Medical Devices Undergoing US Food and Drug Administration 510(k) Clearance and Premarket Approval, 2008-2017.
    Dubin JR; Simon SD; Norrell K; Perera J; Gowen J; Cil A
    JAMA Netw Open; 2021 May; 4(5):e217274. PubMed ID: 33956132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016.
    Moore TJ; Zhang H; Anderson G; Alexander GC
    JAMA Intern Med; 2018 Nov; 178(11):1451-1457. PubMed ID: 30264133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Regulatory Submission Characteristics and Recalls of Medical Devices Receiving 510(k) Clearance.
    Everhart AO; Sen S; Stern AD; Zhu Y; Karaca-Mandic P
    JAMA; 2023 Jan; 329(2):144-156. PubMed ID: 36625811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the safety and effectiveness of devices after US Food and Drug Administration approval: FDA-mandated postapproval studies.
    Reynolds IS; Rising JP; Coukell AJ; Paulson KH; Redberg RF
    JAMA Intern Med; 2014 Nov; 174(11):1773-9. PubMed ID: 25265209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiological Medical Device Innovation: Approvals via the Premarket Approval Pathway From 2000 to 2015.
    Ghobadi CW; Hayman EL; Finkle JH; Walter JR; Xu S
    J Am Coll Radiol; 2017 Jan; 14(1):24-33. PubMed ID: 28061962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age Indications.
    Lee SJ; Cho L; Klang E; Wall J; Rensi S; Glicksberg BS
    JAMA Netw Open; 2021 Jun; 4(6):e2112562. PubMed ID: 34156454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cost of Biotech Innovation: Exploring Research and Development Costs of Cell and Gene Therapies.
    Sabatini MT; Chalmers M
    Pharmaceut Med; 2023 Sep; 37(5):365-375. PubMed ID: 37286928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
    Samuel AM; Rathi VK; Grauer JN; Ross JS
    Clin Orthop Relat Res; 2016 Apr; 474(4):1053-68. PubMed ID: 26584802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019.
    Galkina Cleary E; Jackson MJ; Zhou EW; Ledley FD
    JAMA Health Forum; 2023 Apr; 4(4):e230511. PubMed ID: 37115539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015.
    Gopal AD; Rathi VK; Teng CC; Del Priore L; Ross JS
    Ophthalmology; 2017 Aug; 124(8):1237-1246. PubMed ID: 28501378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
    Prasad V; Mailankody S
    JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements.
    Zheng SY; Dhruva SS; Redberg RF
    JAMA; 2017 Aug; 318(7):619-625. PubMed ID: 28810022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new collaborative path in medical device development: the medical device innovation consortium.
    Kampfrath T; Cotten SW
    Clin Biochem; 2013 Oct; 46(15):1320-2. PubMed ID: 23578741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014.
    Rathi VK; Wang B; Ross JS; Downing NS; Kesselheim AS; Gray ST
    Otolaryngol Head Neck Surg; 2017 Feb; 156(2):285-288. PubMed ID: 28093943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.